FR2847166B1 - Forme posologique comprenant des pastilles de tamsulosine enrobees, son procede de preparation et son utilisation - Google Patents

Forme posologique comprenant des pastilles de tamsulosine enrobees, son procede de preparation et son utilisation

Info

Publication number
FR2847166B1
FR2847166B1 FR0300651A FR0300651A FR2847166B1 FR 2847166 B1 FR2847166 B1 FR 2847166B1 FR 0300651 A FR0300651 A FR 0300651A FR 0300651 A FR0300651 A FR 0300651A FR 2847166 B1 FR2847166 B1 FR 2847166B1
Authority
FR
France
Prior art keywords
pags
tamsulosin
preparing
closed
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0300651A
Other languages
English (en)
Other versions
FR2847166A1 (fr
Inventor
Johannes Jan Platteeuw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2847166(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon BV filed Critical Synthon BV
Publication of FR2847166A1 publication Critical patent/FR2847166A1/fr
Application granted granted Critical
Publication of FR2847166B1 publication Critical patent/FR2847166B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0300651A 2002-11-14 2003-01-22 Forme posologique comprenant des pastilles de tamsulosine enrobees, son procede de preparation et son utilisation Expired - Lifetime FR2847166B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/293,940 US7018658B2 (en) 2002-11-14 2002-11-14 Pharmaceutical pellets comprising tamsulosin

Publications (2)

Publication Number Publication Date
FR2847166A1 FR2847166A1 (fr) 2004-05-21
FR2847166B1 true FR2847166B1 (fr) 2005-06-10

Family

ID=23131212

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0300651A Expired - Lifetime FR2847166B1 (fr) 2002-11-14 2003-01-22 Forme posologique comprenant des pastilles de tamsulosine enrobees, son procede de preparation et son utilisation

Country Status (23)

Country Link
US (1) US7018658B2 (fr)
EP (1) EP1562573B1 (fr)
JP (1) JP5405710B2 (fr)
AT (2) ATE323478T1 (fr)
AU (3) AU2002351451A1 (fr)
BE (1) BE1015435A4 (fr)
CA (1) CA2415840C (fr)
CH (1) CH696419A5 (fr)
CZ (1) CZ13341U1 (fr)
DE (2) DE20219293U1 (fr)
DK (2) DK1562573T3 (fr)
ES (1) ES2257589T3 (fr)
FI (1) FI5842U1 (fr)
FR (1) FR2847166B1 (fr)
GB (1) GB2395125B (fr)
HU (1) HUP0500832A3 (fr)
NL (1) NL1022151C2 (fr)
NO (1) NO20052860L (fr)
PL (1) PL206083B1 (fr)
PT (1) PT1562573E (fr)
SI (1) SI21394A2 (fr)
WO (2) WO2004043449A1 (fr)
ZA (1) ZA200503696B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
NZ535456A (en) * 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
EA200600066A1 (ru) * 2003-07-01 2006-06-30 Крка, Товарна Здравил, Д.Д. Ново Место Тамсулозинсодержащее ядро, покрытое поливинилпирролидоном или поливинилацетатом
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
WO2005053659A1 (fr) * 2003-12-03 2005-06-16 Natco Pharma Limited Preparation pharmaceutique amelioree contenant un sel de tamsulosine et procede de fabrication
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100615952B1 (ko) * 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE502004004032D1 (de) * 2004-07-14 2007-07-19 Siegfried Generics Internat Lt Granulat zur kontrollierten Freisetzung von Tamsulosin, enthaltend Alginat
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007017253A1 (fr) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Preparation orale a liberation controlee d'un benzenesulfonamide
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR100745515B1 (ko) * 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
EP2026766A1 (fr) 2006-05-17 2009-02-25 Synthon B.V. Composition en comprimé pour la libération prolongée de la tamsulosine
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2047847A1 (fr) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique solide comprenant de la tamsulosine
WO2009047312A1 (fr) * 2007-10-12 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Composition pharmaceutique solide comprenant de la tamsulosine
KR20110102339A (ko) * 2008-12-09 2011-09-16 신톤 비.브이. 고정용량 복합제용 탐술로신 펠렛
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
WO2011009604A1 (fr) 2009-07-22 2011-01-27 Grünenthal GmbH Forme galénique inviolable stabilisée à l’oxydation
WO2012028319A1 (fr) 2010-09-02 2012-03-08 Grünenthal GmbH Forme pharmaceutique inviolable comportant un sel inorganique
WO2012110092A1 (fr) 2011-02-17 2012-08-23 Synthon Bv Dérivés de tamsulosine
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
WO2013123965A1 (fr) 2012-02-20 2013-08-29 Synthon Bv Formulation pharmaceutique à dose fixe
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
WO2014203137A2 (fr) 2013-06-21 2014-12-24 Wockhardt Limited Compositions pharmaceutiques de tamsulosine ou ses sels
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
CZ2015225A3 (cs) * 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
WO2017042325A1 (fr) 2015-09-10 2017-03-16 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus
CN105287395A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
MX2018011642A (es) 2016-03-31 2019-03-14 Hanmi Pharm Ind Co Ltd Preparacion en capsula compuesta que contiene tadalafilo y tamsulosina con estabilidad y tasa de elucion mejoradas.
EP3473244A1 (fr) 2017-10-20 2019-04-24 Veru Inc. Chlorhydrate de tamsulosine à libération contrôlée destiné à être administré par voie orale
EP3473245A1 (fr) 2017-10-20 2019-04-24 Veru Inc. Chlorhydrate de tamsulosine à libération contrôlée destiné à être administré par voie orale
CN118284408A (zh) 2021-10-25 2024-07-02 法玛利德尔公司 他达拉非经口混悬剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
JPH07316077A (ja) * 1994-05-20 1995-12-05 Sumitomo Pharmaceut Co Ltd 腸溶性コーティング用組成物
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
EP1064938A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à libération contrôlée avec au moins une impulsion temporelle
ID30249A (id) * 1999-08-09 2001-11-15 Yamanouchi Pharma Co Ltd Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
PT1207860E (pt) * 1999-09-02 2008-01-24 Nostrum Pharmaceuticals Inc Formulação de peletes de libertação controlada
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
PT1443917E (pt) * 2001-11-07 2006-06-30 Synthon Bv Comprimidos de tamsulosina
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
AT6542U1 (de) 2003-12-29
SI21394A2 (sl) 2004-06-30
JP2006508960A (ja) 2006-03-16
HUP0500832A3 (en) 2009-12-28
FR2847166A1 (fr) 2004-05-21
EP1562573A1 (fr) 2005-08-17
US20040096502A1 (en) 2004-05-20
ZA200503696B (en) 2006-08-30
ATE323478T1 (de) 2006-05-15
JP5405710B2 (ja) 2014-02-05
PT1562573E (pt) 2006-07-31
DE60210828T2 (de) 2006-10-19
WO2004043448A1 (fr) 2004-05-27
FIU20020500U0 (fi) 2002-12-16
NL1022151C2 (nl) 2004-05-18
GB0229021D0 (en) 2003-01-15
WO2004043449A1 (fr) 2004-05-27
DE20219293U1 (de) 2003-06-05
CZ13341U1 (cs) 2003-06-02
PL206083B1 (pl) 2010-06-30
NO20052860L (no) 2005-08-10
FI5842U1 (fi) 2003-07-03
DK1562573T3 (da) 2006-08-21
AU2003288083A1 (en) 2004-06-03
AU2003200059A1 (en) 2004-06-03
CA2415840A1 (fr) 2004-05-14
DE60210828D1 (de) 2006-05-24
GB2395125B (en) 2007-06-06
NO20052860D0 (no) 2005-06-13
AU2002351451A1 (en) 2004-06-03
PL357856A1 (en) 2004-05-17
ES2257589T3 (es) 2006-08-01
EP1562573B1 (fr) 2006-04-19
HUP0500832A2 (en) 2007-07-30
GB2395125A (en) 2004-05-19
AU2003200059B2 (en) 2008-07-03
CA2415840C (fr) 2008-11-18
US7018658B2 (en) 2006-03-28
CH696419A5 (de) 2007-06-15
BE1015435A4 (nl) 2005-04-05
DK200300005U3 (da) 2003-04-25

Similar Documents

Publication Publication Date Title
FR2847166B1 (fr) Forme posologique comprenant des pastilles de tamsulosine enrobees, son procede de preparation et son utilisation
FR2880823B1 (fr) Catalyseur d'hydrotraitement, son procede de preparation et et son utilisation
Feuerstein Biomorphic architecture
NO20031273D0 (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
IL174460A0 (en) Fully human antibodies against human 4-ibb (cd137)
FR2858634B1 (fr) Nontisse ultrafin, poreux et mecaniquement stable, son procede de fabrication et son utilisation
BR0117199B1 (pt) dispositivo para realização de osteosìntese.
DE60219271D1 (de) Drucksystem, Druckgerät, Druckverfahren und Druckprogramm
HK1167332A1 (en) Pharmaceutical composition, use thereof and method for making the same
FR2850099B1 (fr) Solide cristallise im-9 et son procede de preparation
DE602004029245D1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
EE04833B1 (et) Meetod suukaudselt manustatava, Tolperisoni või selle soola sisaldava farmatseutilise preparaadi valmistamiseks
ATE394394T1 (de) Arylvinylazacycloalkane verbindungen und methoden zu ihrer herstellung und deren verwendung
FR2880822B1 (fr) Catalyseur d'hydrotraitement, son procede de preparation et son utilisation
ITRM20030153A1 (it) Formulazione idrosolubile contenente ubichinone per uso oftalmico.
NO20022969D0 (no) Sammensetninger og metoder for L-nukleosider, L-nukleotider og analoger derav
DK1539921T3 (da) Indretning til dyrkning af celler, især celler fra mennesker eller dyr
IL164248A0 (en) Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
NO20031844L (no) Nye askorbinsyreforbindelser, fremgangsmåter for fremstilling derav og anvendelse derav
FI20020881A (fi) Iskulaite
NO20053805D0 (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
DE60301594D1 (de) Druckgerät, Druckverfahren und Druckprogramm
IL164815A (en) Halosulfonylbenzoyl halides, processes for their preparation and their use for preparing substituted phenylsulfonylureas
FR2859909B1 (fr) Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
BRPI0310056A2 (pt) método de transpiração térmica, recipiente de transpiração térmica e aparelho de transpiração térmica utilizados para o mesmo

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20